Arvinas
IPOTargeted Protein Degradation Therapeutics
Public · New Haven, United States · Founded 2013 · $464.9M raised
- Headquarters
- New Haven, Connecticut
- Employees
- 201–500
- Founded
- 2013
- Business Model
- B2B
- Website
- arvinas.com
- Total Funding
- $464.9M
- Last Round
- $350.0M Private EquityNov 2023
- Rounds
- 4
- Type
- Public
About
Arvinas is a clinical-stage biopharmaceutical company and pioneer of PROTAC protein degrader technology, harnessing the body's own ubiquitin-proteasome system to selectively degrade disease-causing proteins. Its pipeline spans oncology and neurology, with lead programs targeting the androgen receptor (ARV-110) and estrogen receptor (ARV-471) in partnership with Pfizer. The company's platform addresses historically undruggable targets, offering potential advantages over traditional inhibitor approaches.
Summary
Arvinas is a Biotech company based in New Haven, United States, founded in 2013. It has raised $464.9M in total across 4 rounds, most recently a $350.0M Private Equity round in Nov 2023. Investors include Canaan Partners, 5AM Ventures and EcoR1 Capital.
Tech & App Stack
7 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Nov 2023
Sign up to see all 5 rounds
Series A through Private Equity — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
BridgeBio makes targeted treatments for genetic diseases.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/arvinas"><img src="https://indexed.vc/api/badge/company/arvinas" alt="Arvinas on Indexed.vc" width="260" height="76" /></a>